|
1
|
Ginsberg RJ, Kris MK and Armstrong JG:
Cancer of the lung. Principles and Practice of Oncology. 4th
edition. JB Lippincott; Philadelphia, PA: pp. 673–682. 1993
|
|
2
|
Amano J, Kuwano H and Yokomise H: Thoracic
and cardiovascular surgery in Japan during 2011: Annual report by
the Japanese Association for Thoracic Surgery. Gen Thorac
Cardiovasc Surg. 61:578–607. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Postus PE: Chemotherapy for non-small cell
lung cancer: the experience of the Lung Cancer Cooperative Group of
the European Organization for Research and Treatment of Cancer.
Chest. 113(Suppl 1): 28S–31S. 1997. View Article : Google Scholar
|
|
4
|
Ding L, Getz G, Wheeler DA, et al: Somatic
mutations affect key pathways in lung adenocarcinoma. Nature.
455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun Y, Ren Y, Fang Z, et al: Lung
adenocarcinoma from East Asian never-smokers is a disease largely
defined by targetable oncogenic mutant kinases. J Clin Oncol.
28:4616–4620. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weir BA, Woo MS, Getz G, et al:
Characterizing the cancer genome in lung adenocarcinoma. Nature.
450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gautschi O, Pauli C, Srobel K, et al: A
patient with BRAF V600E lung adenocarcinoma responding to
vemurafenib. J Thorac Oncol. 7:e23–e24. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Falchook GS, Long GV, Kurzrock R, et al:
Dabrafenib in patients with melanoma, untreated brain metastases,
and other solid tumors: a phase 1 dose-escalation trial. Lancet.
379:1893–1901. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chapman PB, Hauschild A, Robert C, et al;
BRIM-3 Study Group. Improved survival with vemurafenib in melanoma
with BRAF V600E mutation. N Engl J Med. 364:2507–2516. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Flaherly KT, Infante JR, Daud A, et al:
Combined BRAF and MEK inhibition in melanoma with BRAF V600E
mutations. N Engl J Med. 367:1694–1703. 2012. View Article : Google Scholar
|
|
11
|
Flaherly KT, Robert C, Hersey P, et al;
METRIC Study Group. Improved survival with MEK inhibition in
BRAF-mutated melanoma. N Engl J Med. 367:107–114. 2012. View Article : Google Scholar
|
|
12
|
Marchetti A, Felicioni L, Malatesta S, et
al: Clinical features and outcome of patients with non-small-cell
lung cancer haboring BRAF mutations. J Clin Oncol. 29:3574–3579.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cardarella S, Ogino A, Nishio M, et al:
Clinical, pathologic, and biologic features associated with BRAF
mutations in non-small cell lung cancer. Clin Cancer Res.
19:4532–4540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sasaki H, Shitara M, Yokota K, et al: Braf
and erbB2 mutations correlate with smoking status in lung cancer
patients. Exp Ther Med. 3:771–775. 2012.PubMed/NCBI
|
|
15
|
Paik PK, Arcila ME, Fara M, et al:
Clinical characteristics of patients with lung adenocarcinomas
haboring BRAF mutations. J Clin Oncol. 29:2046–2051. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sasaki H, Shimizu S, Tani Y, et al:
Usefulness of immunohistochemistry for the detection of the BRAF
V600E mutation in Japanese lung adenocarcinoma. Lung Cancer.
82:51–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pratilas CA, Hanrahan AJ, Halilovic E, et
al: Genetic predictors of MEK dependence in non-small cell lung
cancer. Cancer Res. 68:9375–9383. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wan PT, Garnett MJ, Roe SM, et al; Cancer
Genome Project. Mechanism of activation of the RAF-ERK signaling
pathway by oncogenic mutations of B-RAF. Cell. 116:855–867. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ciampi R, Zhu Z and Nikiforov YE: BRAF
copy number gains in thyroid tumors detected by fluorescence in
situ hybridization. Endocr Pathol. 16:99–105. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Endo K, Sasaki H, Yano M, et al:
Evaluation of the epidermal growth factor receptor gene mutation
and copy number in non-small cell lung cancer with gefitinib
therapy. Oncol Rep. 16:533–541. 2006.PubMed/NCBI
|
|
21
|
Sasaki H, Okuda K, Kawano O, et al: Nras
and Kras mutation in Japanese lung cancer patients: Genotyping
analysis using LightCycler. Oncol Rep. 18:623–628. 2007.PubMed/NCBI
|
|
22
|
Wang TL, Maierhofer C, Speicher MR, et al:
Digital karyotyping. Proc Natl Acad Sci USA. 99:16156–16161. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cardarella S, Ogino A, Nishino M, et al:
Clinical, pathologic, and biologic features associated with BRAF
mutations in non-small cell lung cancer. Clin Cancer Res.
19:4532–4540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Marchetti A, Felicioni L, Malatesta S, et
al: Clinical features and outcome of patients with non-small-cell
lung cancer haboring BRAF mutations. J Clin Oncol. 29:3574–3579.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Oliveira Duarte Achcar R, Nikiforova MN
and Yousem SA: Micropappillary lung adenocarcinoma: EGFR, K-ras,
and BRAF mutational profile. Am J Clin Pathol. 131:694–700. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rudin CM, Hong K and Streit M: Molecular
characterization of acquired resistance to the BRAF inhibitor
dabrafenib in patient with BRAF-mutant non-small-cell lung cancer.
J Thorac Oncol. 8:e41–e42. 2013.PubMed/NCBI
|
|
27
|
El-Naggar AK, Dinh M, Tucker SL, et al:
Numerical chromosomal changes in DNA hypodiploid solid tumors;
restricted loss and gain of certain chromosomes. Cytometry.
37:107–112. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Balsara BR, Sonoda G, du Manoir S, et al:
Comparative genomic hybridization analysis detects frequent, often
high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and
8q in human non-small cell lung carcinomas. Cancer Res.
57:2116–2120. 1997.PubMed/NCBI
|
|
29
|
Ubagai T, Matsuura S, Tauchi H, et al:
Coparative genomic hybridization analysis suggests a gain of
chromosome 7p associated with lymph node metastasis in non-small
cell lung cancer. Oncol Rep. 8:83–88. 2001.
|
|
30
|
Garnis C, Lockwood WW, Vucic E, et al:
High resolution analysis of non-small cell lung cancer cell lines
by whole genome tiling path array CGH. Int J Cancer. 118:1556–1564.
2006. View Article : Google Scholar
|
